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Objective: In the past decennium, the management of short-neck infrarenal and juxtarenal aortic aneurysms with fenes-
trated endovascular aneurysm repair (FEVAR) has been shown to be successful, with good early and midterm results.
Recently, a new fenestrated device, the fenestrated Anaconda (Vascutek, Renfrewshire, Scotland), was introduced. The
aim of this study was to present the current Dutch experience with this device.
Methods: A prospectively held database of patients treated with the fenestrated Anaconda endograft was analyzed. Decision
to treat was based on current international guidelines. Indications for FEVAR included an abdominal aortic aneurysm
(AAA) with unsuitable neck anatomy for EVAR. Planning was performed on computed tomography angiography images
using a three-dimensional workstation.
Results: BetweenMay 2011 and September 2013, 25 patients were treated in eight institutions for juxtarenal (n[ 23) and
short-neck AAA (n [ 2). Median AAA size was 61 mm (59-68.5 mm). All procedures except one were performed with
bifurcated devices. A total of 56 fenestrations were incorporated, and 53 (94.6%) were successfully cannulated and stented.
One patient died of bowel ischemia caused by occlusion of the superiormesenteric artery.On completion angiography, three
type I endoleaks and seven type II endoleaks were observed. At 1 month of follow-up, all endoleaks had spontaneously
resolved. Median follow-up was 11 months (range, 1-29 months). There were no aneurysm ruptures or aneurysm-related
deaths and no reinterventions to date. Primary patency at 1 month of cannulated and stented target vessels was 96%.
Conclusions: Initial and short-term results of FEVAR using the fenestrated Anaconda endograft are promising, with
acceptable technical success and short-term complication rates. Growing experience and long-term results are needed to
support these ﬁndings. (J Vasc Surg 2014;60:301-7.)In the past 2 decades, endovascular aneurysm repair
(EVAR) has evolved rapidly and has proven to be a good
alternative to open repair in the treatment of infrarenal
abdominal aortic aneurysms (AAAs). Advantages of
EVAR include reduced periprocedural mortality, reduced
postoperative complications, less blood transfusion require-
ment, and shorter hospital stay.1-4 A variety of standard
commercial devices are available for infrarenal EVAR. Stan-
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(short neck length <15 mm, angulation >60, a reversed
conical neck, or aneurysm involvement of important aortic
side-branch vessels).
Fenestrated and branched endografts have been devel-
oped for the treatment of these complex aneurysms. The
use of fenestrated endografts was ﬁrst introduced in
1996, and the subsequent evolution in devices and delivery
systems has been enormous.5 In the past decennium, the
management of short-neck infrarenal, juxtarenal, and su-
prarenal aortic aneurysms with fenestrated endovascular
aneurysm repair (FEVAR) has been shown to be successful,
with good early and midterm results.6-8 Most of the accu-
mulated experience has involved the Zenith (Cook Medical
Australia, Brisbane, Queensland, Australia) custom-made
fenestrated endograft.
Recently, the new Fenestrated Anaconda Endograft
(Vascutek, Renfrewshire, Scotland) was introduced for
the treatment of juxtarenal and infrarenal AAAs with a
short neck. Potential advantages of the endograft include
the ability to reposition the body with a controlled deploy-
ment system, the ability to position the superior mesenteric
(SMA) or celiac artery (CA) in an anterior augmented
scallop, the ability to cannulate target vessels using axillary
access, and the lack of stent material compromising the
position of the fenestrations. The initial experiences with
this new device were published in 2011 by Bungay et al.9301
Fig 1. Illustrations of the fenestrated Anaconda show (a) the endograft with the top stents collapsed, (b) the endograft
after deployment, and (c) the endograft in situ. In this case, a three-fenestration device with a valley for the celiac artery
(CA) was used. (Figure provided by Vascutek, Renfrewshire, Scotland.)
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rience with the fenestrated Anaconda endograft.METHODS
Design of the study. A prospectively held database
was retrospectively analyzed. Research collaborators at
the respective hospitals prospectively collected the data,
which were entered into a centrally kept database. All
patients underwent preoperative assessment using
multislice-detector computed tomography angiography
(CTA). The decision to treat was according to current
international guidelines.10,11 Indications for FEVAR
included an AAA with unsuitable neck anatomy for con-
ventional EVAR (aortic neck length <15 mm, neck
angulation >60, conical neck). Planning was performed
from CTA images and multiplanar reconstructions on a
three-dimensional (3D) workstation. The procedures took
place in a hybrid suite equipped for interventional radi-
ology and open surgical procedures or in a surgical theater
using a recent-generation mobile C-arm.
Follow-up consisted of CTA at 1 month and 1 year,
and CTA scanning every other year thereafter. Given the
data were anonymous and analysis performed retrospec-
tively, the study was exempted from Institutional Review
Board approval.Description of the fenestrated Anaconda endo-
graft. The fenestrated Anaconda endograft is a new cus-
tomizable device for individual patient use and is based
on the Anaconda AAA endograft system (Conformité
Européene approved).12 The device is trimodular and
consists of a dual proximal ring stent with two or four
ﬁxation hooks (depending of the conﬁguration of the
fenestrations), an unsupported graft body that facilitates
the nitinol-reinforced fenestrations, and a distal ringed
stent. A range of endograft conﬁgurations is currently
available, allowing for one up to four fenestrations. Also,
the addition of an augmented valley (comparable to a
scallop) and a bifurcated or a tube design add further
possibilities to treat AAAs with a various range of anatomy
(Fig 1). The instructions for use advise oversizing the main
device by 10% to 20%. The outer diameter of the main
device introducer is 20F or 23F, depending on the size.
Construction time for the device is w6 weeks.
The fenestrated Anaconda has several special features
that are new. It can be repositioned after full deployment,
allowing for accurate deployment and easy repositioning of
the endograft body and its fenestrations. The fenestrations
are placed in the unsupported region, in this way maxi-
mizing the area available and potentially allowing for easier
alignment and subsequent cannulation of target vessels.
The lack of columnar strength combined with a ringed
Table I. Demographic and operative characteristics
Variable Value
Gender, No. (%)
Male 22 (88)
Female 3 (12)
Age, mean 6 SD, years 73 6 7.1
Comorbidities,a No. (%)
Diabetes mellitus 3 (12)
Hypertension 15 (60)
Hypercholesterolemia 9 (36)
Current smoker 9 (36)
Cardiac disease 18 (72)
Pulmonary disease 3 (12)
Renal disease 8 (32)
ASA score, No. (%)
2 12 (48)
3 12 (48)
4 1 (4)
Aneurysm anatomy, No. (%)
Juxtarenal 23 (92)
Short neck 2 (8)
AAA diameter, median (IQR), mm 61 (55-88)
Number of fenestrations,b No. (%)
1 3 (12)
2 15 (60)
3 5 (20)
4 2 (8)
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesi-
ologists (ASA) Physical Status Classiﬁcation; IQR, interquartile range; SD,
standard deviation.
aDeﬁnitions: Diabetes includes patients being treated with oral antidiabetic
medication or insulin. Hypertension includes diastolic blood pressure
>90 mm Hg uncontrolled or controlled by medication. Hypercholester-
olemia includes uncontrolled or controlled by medication. Cardiac disease
includes congestive heart failure, coronary artery disease, and previous
myocardial infarction. Pulmonary disease includes chronic obstructive pul-
monary disease Global Initiative for Chronic Obstructive Lung Disease $2.
Renal disease is indicated by an estimated glomerular ﬁltration
rate <60 mL/min/1.73 m2.11
bFor detailed stent conﬁguration, see the Methods section.
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lated and stenotic anatomy.
Preoperatively, a 3D model of each patient’s aorta was
made and a test run performed using an exact copy of the
endograft that was planned to be implanted. This allowed
for ex vivo visualization of the endograft and fenestration
position and also for radiographically controlled cannula-
tion of fenestrations with wires and catheters.
Stent implantation. Bilateral open femoral access was
obtained. All patients received 5000 U of heparin before
femoral artery cannulation, with additional boluses of hep-
arin added intraoperatively depending on the length of the
procedure. After introduction and deployment of the
fenestrated main body, the fenestrations and target vessels
were cannulated, guided by the four radiopaque markers at
each fenestration and by the radiopaque saddle-shaped top
stents (Fig 1). At this point, angiography was performed to
conﬁrm the position. If not satisfactory, the control and
release wires could be used to collapse the top ring stent
and the device repositioned to achieve a more satisfactory
position. Once the graft was in place, the target vessels
were provided with covered stents using standard endo-
vascular techniques,whichwereﬂaredwitha12-mm20-mm
balloon. Finally, the limb extensions were placed, and a
completion angiogram was performed.
Deﬁnitions. Juxtarenal was deﬁned as an aneurysm
that abutted the renal arteries but did not involve the renal
arteries (no normal aorta between upper extent of aneu-
rysm and renal arteries). Short neck was deﬁned as an aneu-
rysm with a normal portion of the aorta between the upper
extent of the aneurysm and lowest renal artery and with a
neck length <15 mm.
Technical success was deﬁned as the successful intro-
duction and deployment of the device in the absence of
surgical conversion or death, type I or III endoleaks, or
graft limb obstruction #24 hours postoperatively.
Clinical success (initial and short-term) was deﬁned as
successful deployment of the endovascular device at the
intended location without death as a result of aneurysm-
related treatment, type I or III endoleak, graft infection
or thrombosis, aneurysm expansion (diameter >5 mm or
volume >5%), aneurysm rupture, or conversion to open
repair. Graft dilatation of $20% by diameter, graft migra-
tion, or a failure of device integrity were classiﬁed as a clin-
ical failure.13
Statistics. Data analysis was performed using SPSS
20.0 software (IBM Corp, Armonk, NY). Continuous vari-
ables are described as mean 6 standard deviation or as me-
dian and interquartile range (IQR) in case of skewed data.
Differences between continuous variables were tested using
a paired Student t-test. Two-sided P values of <.05 were
considered signiﬁcant.
RESULTS
BetweenMay2011 andSeptember 2013, 25procedures
were performed at eight institutions in The Netherlands.
Patient demographics are reported in Table I. Mean aneu-
rysm size was 64 6 8.8 mm. AAAs were juxtarenal in 23patients (92%), and the remaining two had a short neck
(3 and 6 mm). Eleven patients were deemed suitable for
both open surgical repair and EVAR.
Three endografts had one fenestration (12%), 15
endografts (60%) had two fenestrations, of which 14 incor-
porated both renal arteries, and one endograft incorpo-
rated a renal artery and the SMA. Five endografts (20%)
had three fenestrations incorporating the left and right
renal artery and the SMA. Two endografts had four fenes-
trations incorporating both renal arteries, the SMA and the
CA. Median aortic diameter at the level of the proximal
landing zone was 26 mm (IQR, 24.5-27.3 mm). All except
one were bifurcated devices. The patient treated with an
aortouni-iliac device had previously been treated with an
infrarenal device, which was then complicated by graft
migration due to neck dilatation and occlusion of the left
limb. Devices were oversized by a median 17.3% (IQR,
16.7%-23.1%).
A total of 56 fenestrations were incorporated, and of
these, 53 (94.6 %) were successfully cannulated and
stented. Full procedural details are reported in Table II.
Table II. Procedural details and follow-up
Details Valuea
Procedures performed per institution, No. 3 (1-5)
Fluoroscopy time, minutes 67 (53-107)
Operative time, minutes 240 (190-356)
Contrast dose, mL 194 (103-320)
Technical success 21 (84)
Clinical success 23 (92)
Graft repositioned
Yes 16 (64)
No 5 (20)
Unknown 4 (16)
Early complications (<30 days)
Compartment syndrome left lower leg 1 (4)
Rupture of common iliac artery 1 (4)
Occluded SMA 1 (4)
Perforation of a renal artery 2 (8)
Cutaneous bleeding 1 (4)
Type I endoleakb 3 (12)
Type II endoleakb 7 (28)
Late complications (>30 days)
Hemorrhagic CVA 1 (4)
Renal function
eGFR, mL/min/1.73 m2
Preoperative 61 6 16
Postoperative at 1 month 56 6 19c
Creatinine, mmol/L
Preoperative 103 6 30
Postoperative 115 6 56d
CVA, Cerebrovascular accident; eGFR, estimated glomerular ﬁltration rate;
IQR, interquartile range; SMA, superior mesenteric artery.
aContinuous data are shown as the median (IQR) or mean 6 standard
deviation, and categoric data are shown as number (%).
bSpontaneously resolved at the 1month follow-up, no reintervention to date.
cP ¼ .07.
dP ¼ .249.
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due to steep downward angulated target vessels. In 16 pa-
tients (64%), the endograft was repositioned. One ancillary
left renal artery ruptured during covered stent expansion,
which was subsequently treated with an occluding Amplat-
zer plug (St. Jude Medical, St. Paul, Minn). In this case, an
ancillary renal artery was cannulated instead of the main
renal artery for which the covered stent was measured.
This also led to occlusion of the main renal artery, as
seen on follow-up CTA, although there was contrast
uptake by the kidney and renal function did not suffer.
Cannulation of the CA through the fenestration was
not successful in one patient. Completion angiography
showed retrograde ﬁlling of the CA through collateral
circulation, without signs of an endoleak. The situation
was accepted, and these ﬁndings were conﬁrmed on the
1-month follow-up CTA.
One SMA occluded #24 hours postoperatively
because of inadequate alignment of the SMA fenestration
and the SMA origin. During the procedure, the marker
of the guiding sheath seemed appropriately located in the
valley of the main body and origin of the SMA in two plains
(angiography). In retrospect, however, the operators
concluded that the main body was not positioned asplanned, but rotated by 15. A CTA the day after surgery
showed that the SMA stent was positioned between the
aortic wall and the main body of the endograft, which
led to occlusion of the SMA origin (Fig 2). The SMA
was supplied with blood through the gastroduodenal ar-
tery. Trashing of thrombus, mainly to the kidneys and
visceral arteries, also occurred during the same procedure.
The endograft was repositioned once during the case,
and the right common iliac artery ruptured during deploy-
ment and was subsequently overstented using the
(covered) right limb extension. These complications led
to renal failure and bowel ischemia, for which a laparotomy
and a left extended hemicolectomy were performed the day
after surgery. Subsequently, the patient developed myocar-
dial ischemia and multiorgan failure and died. One patient
developed a compartment syndrome of the left lower leg
postoperatively, for which a fasciotomy was performed.
All renal arteries were stented using the Advanta V12
covered stent (Atrium, Hudson, NH). In two fenestra-
tions, a bare-metal stent was used instead of a covered stent
(one for the SMA and one for the CA).
Completion angiography showed three type I endo-
leaks, which spontaneously resolved on the 1-month
follow-up CTA (Fig 3), seven type II endoleaks, and no
type III endoleaks. At the 1-month follow-up, there were
no endoleaks. No aneurysm growth was observed on 1-
month follow-up CTA.
Median follow-up was 11 months (IQR, 1-29 months).
There were no aneurysm ruptures. One patient died of
bowel ischemia as a result of an occluded SMA. Another
patient died of hemorrhagic stroke 3 months postopera-
tively, which was attributed to the use of antiplatelet
agents. There were no reinterventions to date.
DISCUSSION
This study shows that the fenestrated Anaconda
endograft can be used safely and effectively and offers an
alternative for the treatment of short-necked infrarenal
and juxtarenal AAAs. In this relatively small series, an
acceptable technical success rate was achieved. The occur-
rence of endoleaks in this series grossly corresponded to
the prevalence reported in previous studies.14 Type II
endoleaks are known to often resolve spontaneously. The
type I endoleaks seen on completion angiography all disap-
peared as well. Further research is necessary, but the fenes-
trated Anaconda seems to do well, even in case of a mild
type I proximal endoleak. One reason might be that the
double saddle-shaped nitinol top ring needs some time to
fully expand and adapt to the speciﬁc neck anatomy.
The fenestrated Anaconda has the possible advantage
of being repositionable. After partial or full deployment,
the saddle-shaped top part of the device can be collapsed,
allowing for rotation and craniocaudal repositioning. In
earlier reports on the use of the Anaconda for infrarenal
AAA repair, the endograft was repositioned in 10% to
38% of the cases to achieve a more satisfactory posi-
tion.15-17 Accurate placement of the device is especially
important in FEVAR, where alignment between the
Fig 2. Inadequate placement of the superior mesenteric artery (SMA) stent in the augmented valley of the main
body led to an occlusion in one patient. During the procedure, the marker of the guiding sheath seemed to be
located in the valley of the main body in two plains (angiography). In retrospect, however, the operators believe
the main body itself was not positioned in the right angle. The ﬁgure shows (a) the angiogram with cannulation of
the SMA with a guiding sheath, (b) angiogram in the left anterior oblique position with a guidewire in the SMA, and
(c) computed tomography angiography (CTA) showing the stent positioned between the aortic wall and the main
body of the endograft.
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cessful target vessel cannulation and stenting. Combined
with the unsupported main body, the possibility to reposi-
tion may allow for more versatility when cannulating the
target vessels. In four patients in this series, there was no
record whether the endograft was repositioned. In 16 pa-
tients (64%), the endograft was repositioned, suggesting
this is a much-used feature. However, it poses the question
whether this is due to design features that predispose to
inaccurate primary placement or simply having the option
to reposition and therefore doing so.
Another feature is the unsupported midportion of the
graft, allowing for more versatility and also allowing fenes-
trations to be placed close to each other. This may be a
beneﬁt in planning and customizing. However, during
ex vivo deployment and repositioning, the operators
observed that an intussusception could occur where the
top supported portion of the graft slides into the unsup-
ported body. Partial deployment up to the level of the fen-
estrations, followed by cannulation of the target vessels
from an axillary approach and eventually full deployment
of the device, could overcome this problem when antici-
pated preoperatively.
In addition, the device has been adapted with addi-
tional supporting suture lines. Also, the relative lack of
support in the area of the fenestrations can lead to
fenestration-to-target vessel mismatch because of anincreased range of motion of the unsupported fabric. This
was observed in one of the patients, in whom an ancillary
renal artery was cannulated instead of the main renal artery.
Another disadvantage of the possibility to reposition
the endograft is that embolization of thrombotic material
lining the aneurysm can occur. This happened in one
patient and led to kidney failure and at least added to
ischemia of the large bowel and, ultimately, to the patient’s
death. In this speciﬁc case, the endograft was repositioned
once during the procedure. Nonetheless, the occurrence of
thromboembolic events warrants a careful approach with
regard to repositioning the device.
Most of the experience using fenestrated endografts, in
The Netherlands and worldwide, is with the Zenith-based
device (Cook Inc, Bloomington, Ind). As with all fenes-
trated devices, the fenestrated Anaconda is customized to
ﬁt the speciﬁc patient’s anatomy. This calls for careful plan-
ning and collaboration with the manufacturer. In some
cases, measurements were adjusted as a result of the test
on the 3D model of the patient’s aorta.
All procedures were performed by a team consisting of
a vascular surgeon, with or without an interventional radi-
ologist. Personnel in all institutions were trained and made
familiar with FEVAR procedures. A relatively long median
operative time and high contrast dose were observed in this
series. Several factors might have contributed to this. As
with any new device one would expect a learning curve.
Fig 3. a, A preoperative computed tomography angiography (CTA) three-dimensional (3D) reconstruction shows
a short-necked aneurysm. b, A completion angiogram shows patent target vessels and a small type I endoleak. c, A 3D
reconstruction of the 1-month follow-up CTA shows the endograft in situ. Review of early-phase and late-phase images
showed that the endoleak had spontaneously resolved.
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FEVAR with this device.
Furthermore, compared with other devices, the fenes-
trated Anaconda might allow for treatment of more com-
plex anatomy due to speciﬁc design features. In a number
of patients, the Cook fenestrated device was deemed unfa-
vorable because of the proximity of target vessels, which
could have resulted in a selection bias.
The operative time and ﬂuoroscopy time were com-
parable to those in initial series reporting on the use of
other endografts. Contrast dose was slightly higher in
this series compared with early experiences with the
Cook device (194 vs 170 mL).18,19 This might be due
to the option to reposition the endograft, in which case
angiography is often performed to verify the adequacy
of the new position. However, compared with the
recently introduced Ventana fenestrated device (Endolo-
gix, Inc, Irvine, Calif), the contrast dose is slightly less
(194 vs 254 mL).20
There have been no reinterventions to date during
follow-up. This series achieved a satisfying technical and
clinical success rate. Further studies are needed to evaluate
long-term outcome, applicability, and actual differences be-
tween available devices.
A limitation of the endograft is the maximum diameter
of 34 mm for the main device, which might pose a problem
when treating an aneurysm with a large diameter proximal
landing zone. The fenestrated Anaconda instructions for
use are based on the standard Anaconda platform and
dictate a 10% to 20% oversize for optimal sealing. Long-
term results will clarify whether this is true for juxtarenal
aneurysms, speciﬁcally in terms of late occurrence of prox-
imal type I endoleaks or migration, or both.
Limitations of the study include the relative small num-
ber of patients and the short-term follow-up, which makesit difﬁcult to draw conclusions about patient outcome
other than clinical success. Especially, the low rate of rein-
tervention and occurrence of endoleaks should be inter-
preted with caution. No aneurysm growth was observed,
but this could be expected, and ongoing surveillance and
follow-up are needed to conﬁrm this.
CONCLUSIONS
The initial and short-term results of FEVAR using the
fenestrated Anaconda endograft are promising, with satis-
fying technical success and short-term complication rates.
Growing experience, midterm results, and long-term re-
sults are needed to support these ﬁndings.
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